These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 8960544)

  • 21. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
    Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
    J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
    Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
    Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
    Storey RF; May JA; Wilcox RG; Heptinstall S
    Thromb Haemost; 1999 Oct; 82(4):1307-11. PubMed ID: 10544919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of GPIIb/IIIa inhibitors in cardiovascular medicine.
    Ahrens I; Peter K; Bode C
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):233-42. PubMed ID: 15030283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
    Dangas G; Fuster V
    Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bitistatin-functionalized fluorescent nanodiamond particles specifically bind to purified human platelet integrin receptor α
    Marcinkiewicz C; Gerstenhaber JA; Sternberg M; Lelkes PI; Feuerstein G
    Int J Nanomedicine; 2017; 12():3711-3720. PubMed ID: 28553109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of Tetrazolo-Fused Benzodiazepines and Benzodiazepinones by a Two-Step Protocol Using an Ugi-Azide Reaction for Initial Diversity Generation.
    Gunawan S; Ayaz M; De Moliner F; Frett B; Kaiser C; Patrick N; Xu Z; Hulme C
    Tetrahedron; 2012 Jul; 68(27-28):5606-5611. PubMed ID: 22923851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. General one-pot, two-step protocol accessing a range of novel polycyclic heterocycles with high skeletal diversity.
    Xu Z; Ayaz M; Cappelli AA; Hulme C
    ACS Comb Sci; 2012 Aug; 14(8):460-4. PubMed ID: 22746181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of G protein-coupled receptor crystallography for drug discovery.
    Salon JA; Lodowski DT; Palczewski K
    Pharmacol Rev; 2011 Dec; 63(4):901-37. PubMed ID: 21969326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging molecular diversity from the intra-molecular Ugi reaction: iterative efficiency in medicinal chemistry.
    Hulme C; Dietrich J
    Mol Divers; 2009 May; 13(2):195-207. PubMed ID: 19205916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The maximal affinity of ligands.
    Kuntz ID; Chen K; Sharp KA; Kollman PA
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):9997-10002. PubMed ID: 10468550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.
    Malonne H; Langer I; Kiss R; Atassi G
    Clin Exp Metastasis; 1999 Feb; 17(1):1-14. PubMed ID: 10390141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
    Maree A; Fitzgerald DJ
    Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
    Samanen JM; Ali FE; Barton LS; Bondinell WE; Burgess JL; Callahan JF; Calvo RR; Chen W; Chen L; Erhard K; Feuerstein G; Heys R; Hwang SM; Jakas DR; Keenan RM; Ku TW; Kwon C; Lee CP; Miller WH; Newlander KA; Nichols A; Parker M; Peishoff CE; Rhodes G; Ross S; Shu A; Simpson R; Takata D; Yellin TO; Uzsinskas I; Venslavsky JW; Yuan CK; Huffman WF
    J Med Chem; 1996 Dec; 39(25):4867-70. PubMed ID: 8960544
    [No Abstract]   [Full Text] [Related]  

  • 36. From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus.
    Blackburn BK; Lee A; Baier M; Kohl B; Olivero AG; Matamoros R; Robarge KD; McDowell RS
    J Med Chem; 1997 Feb; 40(5):717-29. PubMed ID: 9057858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.